Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19295129 | Healthcare Object Recognition, Systems And Methods | August 2025 | March 2026 | Allow | 7 | 0 | 0 | Yes | No |
| 19059016 | CONTEXT-BASED USER INTERFACE TO MEDICAL DATABASE | February 2025 | March 2026 | Allow | 13 | 0 | 0 | Yes | No |
| 19057625 | SYSTEM, METHOD AND APPARATUS FOR REAL-TIME ACCESS TO NETWORKED RADIOLOGY DATA | February 2025 | February 2026 | Allow | 12 | 0 | 0 | Yes | No |
| 19020852 | ALARM NOTIFICATION SYSTEM | January 2025 | February 2026 | Allow | 13 | 0 | 0 | Yes | No |
| 18988507 | SYSTEM AND METHOD FOR IDENTIFYING CANDIDATES FOR CLINICAL TRIALS | December 2024 | February 2026 | Allow | 14 | 0 | 0 | Yes | No |
| 18821076 | Healthcare Object Recognition, Systems And Methods | August 2024 | November 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18821950 | METHOD TO INCREASE EFFICIENCY, COVERAGE, AND QUALITY OF DIRECT PRIMARY CARE | August 2024 | October 2025 | Allow | 14 | 0 | 0 | No | No |
| 18794726 | INTEGRATED, AI-ENABLED VALUE-BASED CARE MEASUREMENT AND OBJECTIVE RISK ASSESSMENT CLINICAL AND FINANCIAL MANAGEMENT SYSTEM | August 2024 | January 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 18673319 | CLINICAL TRIAL SUPPORT APPARATUS, OPERATION METHOD OF CLINICAL TRIAL SUPPORT APPARATUS, AND OPERATION PROGRAM OF CLINICAL TRIAL SUPPORT APPARATUS | May 2024 | February 2026 | Allow | 21 | 0 | 0 | Yes | No |
| 18651634 | System and Method for Automated Dosage Calculation and Patient Treatment Life Cycle | April 2024 | January 2025 | Allow | 9 | 0 | 0 | Yes | No |
| 18651438 | ALARM NOTIFICATION SYSTEM | April 2024 | December 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18600551 | VALENCE PROFILING OF VIRTUAL INTERACTIVE OBJECTS | March 2024 | November 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18400093 | Method for Applying Analytics Through Artificial Intelligence for Delivering Medical Care | December 2023 | November 2025 | Allow | 23 | 0 | 0 | Yes | No |
| 18481594 | SENIOR LIVING ENGAGEMENT AND CARE SUPPORT PLATFORMS | October 2023 | July 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18463031 | SYSTEM FOR PROCESSING RETAIL CLINIC CLAIMS | September 2023 | June 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18446961 | SYSTEM, METHOD AND APPARATUS FOR REAL-TIME ACCESS TO NETWORKED RADIOLOGY DATA | August 2023 | November 2024 | Allow | 15 | 1 | 0 | No | No |
| 18061560 | VALENCE PROFILING OF VIRTUAL INTERACTIVE OBJECTS | December 2022 | November 2025 | Allow | 36 | 4 | 1 | Yes | No |
| 17979098 | CONTEXT-BASED USER INTERFACE TO MEDICAL DATABASE | November 2022 | November 2024 | Allow | 25 | 0 | 0 | Yes | No |
| 17964358 | DEVICES, SYSTEMS, AND METHODS FOR PROVIDING REMOTE SUPPORT TO A USER OF CARE COMPONENTS | October 2022 | December 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17843044 | HEALTH MANAGEMENT AND GUIDANCE INSTRUCTION ISSUANCE ASSISTANCE | June 2022 | February 2026 | Allow | 44 | 3 | 1 | No | No |
| 17840894 | SURGICAL SUPPORT SYSTEM, SURGICAL SUPPORT METHOD, AND INFORMATION STORAGE MEDIUM | June 2022 | March 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17805452 | System and Method for Coordinating Care within the Health Industry | June 2022 | November 2024 | Abandon | 29 | 2 | 0 | Yes | No |
| 17826476 | SYSTEM AND METHOD FOR IDENTIFYING CANDIDATES FOR CLINICAL TRIALS | May 2022 | October 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17824838 | SYSTEM FOR DETERMINING CLINICAL TRIAL PARTICIPATION | May 2022 | August 2024 | Allow | 27 | 0 | 0 | No | No |
| 17725368 | SENIOR LIVING ENGAGEMENT AND CARE SUPPORT PLATFORMS | April 2022 | October 2024 | Allow | 30 | 4 | 1 | Yes | No |
| 17508110 | SYSTEMS AND METHODS FOR PREFERENCE ELICITATION ON CAR DESIGNS | October 2021 | February 2026 | Abandon | 52 | 6 | 0 | Yes | No |
| 17441881 | HIGHLY RELIABLE DATA TRANSACTION SYSTEM, AND HIGHLY RELIABLE DATA TRANSACTION METHOD | September 2021 | May 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17375916 | SYSTEMS AND METHODS FOR PROVIDING ACCURATE PATIENT DATA CORRESPONDING WITH PROGRESSION MILESTONES FOR PROVIDING TREATMENT OPTIONS AND OUTCOME TRACKING | July 2021 | June 2024 | Abandon | 35 | 5 | 1 | Yes | No |
| 17350156 | HEALTH MANAGING METHOD AND STORAGE MEDIUM | June 2021 | November 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 17335688 | ERGONOMIC MONITORING AND ANALYSIS FOR AN OPERATING ROOM | June 2021 | May 2025 | Abandon | 48 | 4 | 1 | Yes | No |
| 17140959 | SYSTEMS AND METHODS OF MEDICAL DEVICE DATA COLLECTION AND PROCESSING | January 2021 | July 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17257503 | Enterprise Consumer Safety System | December 2020 | February 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17102818 | TREATMENT PLAN IDENTIFICATION | November 2020 | June 2025 | Abandon | 55 | 4 | 1 | Yes | No |
| 16988146 | METHOD, SYSTEM, AND DEVICE FOR PROVIDING ASSISTANCE TO PATIENTS WITH COMMUNICATION AND MEMORY IMPAIRMENT | August 2020 | September 2024 | Allow | 49 | 4 | 1 | No | No |
| 16889210 | Systems and Methods for Managing Patient Medical Devices | June 2020 | March 2025 | Allow | 57 | 4 | 0 | Yes | No |
| 16696981 | TECHNIQUES TO ASSIST IN DIAGNOSIS AND TREATMENT OF INJURY AND ILLNESS | November 2019 | May 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16498584 | SMARTPHONE APP FOR DOSE CAPTURE AND METHOD | September 2019 | April 2025 | Abandon | 60 | 7 | 0 | No | No |
| 14832234 | DETECTION OF ABUSIVE PRESCRIBING OF CONTROLLED SUBSTANCES | August 2015 | December 2024 | Abandon | 60 | 11 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BURGESS, JOSEPH D.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BURGESS, JOSEPH D works in Art Unit 3685 and has examined 13 patent applications in our dataset. With an allowance rate of 30.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner BURGESS, JOSEPH D's allowance rate of 30.8% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BURGESS, JOSEPH D receive 4.46 office actions before reaching final disposition. This places the examiner in the 99% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BURGESS, JOSEPH D is 49 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +8.3% benefit to allowance rate for applications examined by BURGESS, JOSEPH D. This interview benefit is in the 39% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 10.0% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 3% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 2% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.